News & Updates

Show Multimedia Only

Temozolomide beyond 6 months tied to better survival in glioblastoma

28 Mar 2023

More than 6 cycles of extended adjuvant temozolomide (TMZ) therapy may result in better overall (OS) and progression-free survival (PFS) in patients with glioblastoma multiform, suggests a study.

28 Mar 2023

Chemotherapy plus ICI treatment ups VTE risk in cancer patients

27 Mar 2023

Combination treatment with immune checkpoint inhibitors (ICI) and chemotherapy is associated with a higher risk of venous thromboembolic events (VTE) in adult cancer patients, reveals a study. In addition, a similar VTE disease course is seen after ICI exposure, irrespective of other immune-related adverse events (irAEs).

27 Mar 2023

Dual inhibition of EGFR, VEGF improves progression-free survival in NSCLC

26 Mar 2023

Inhibiting the pathways of both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) leads to significant improvements in progression-free survival (PFS) but more adverse events (AEs), results of a meta-analysis have shown.

26 Mar 2023

$Add-on pembrolizumab helps improve outcomes of relapsed, refractory Hodgkin lymphoma$

Add-on pembrolizumab helps improve outcomes of relapsed, refractory Hodgkin lymphoma

25 Mar 2023

Adding pembrolizumab to chemotherapy consisting of ifosfamide, carboplatin, and etoposide (ICE) in the treatment of patients with relapsed or refractory classic Hodgkin lymphoma appears to be well tolerated and associated with better outcomes in comparison with reports from studies on chemotherapy-only regimens, according to data from a phase II study.

25 Mar 2023

$Add-on vistusertib misses mark in platinum-resistant, refractory ovarian high-grade serous carcinoma$

Add-on vistusertib misses mark in platinum-resistant, refractory ovarian high-grade serous carcinoma

25 Mar 2023

Adding vistusertib to weekly paclitaxel does not appear to help improve clinical outcomes in patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC), according to the results of a phase II study.

25 Mar 2023

Atorvastatin cardioprotective in lymphoma patients receiving anthracycline?

25 Mar 2023 by

Among patients with lymphoma receiving anthracycline-based chemotherapy, those who received atorvastatin for 12 months were significantly less likely to experience a cardiac dysfunction than those on placebo, according to the STOP-CA* trial presented at ACC.23/WCC.

25 Mar 2023

Use of monitoring tests remains low in prostate cancer

23 Mar 2023

Low use of recommended monitoring tests, including repeat prostate biopsy, persists among patients with localized prostate cancer undergoing observation, a recent study has found.

23 Mar 2023

Response to therapy higher in clinical trial than real-world RCC patients

22 Mar 2023

Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.